dc.contributor
Institut Català de la Salut
dc.contributor
[de Melo Gagliato D] Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, São Paulo, Brazil. [Buzaid AC] Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, São Paulo, Brazil. Centro Oncológico Hospital Israelita Albert Eisntein, São Paulo, Brazil. [Perez-Garcia JM, Llombart A] Baselga Institute of Oncology, Quiron University Hospital Barcelona, Barcelona, Spain. [Cortes J] Ramon y Cajal University Hospital, Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
de Melo Gagliato, Debora
dc.contributor.author
Buzaid, Antonio C
dc.contributor.author
Perez-Garcia, Jose Manuel
dc.contributor.author
Llombart-Cussac, Antonio
dc.contributor.author
Cortés Castan, Javier
dc.date.accessioned
2025-10-25T05:38:11Z
dc.date.available
2025-10-25T05:38:11Z
dc.date.issued
2021-08-26T11:40:50Z
dc.date.issued
2021-08-26T11:40:50Z
dc.date.issued
2020-09-01
dc.identifier
de Melo Gagliato D, Buzaid AC, Perez-Garcia JM, Llombart A, Cortes J. CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. Cancers. 2020 Sep 1;12(9):2480.
dc.identifier
https://hdl.handle.net/11351/6241
dc.identifier
10.3390/cancers12092480
dc.identifier
000581446700001
dc.identifier.uri
http://hdl.handle.net/11351/6241
dc.description.abstract
Inhibidors de CDK4/6; Càncer de mama amb receptor hormonal positiu; Càncer de mama metastàtic
dc.description.abstract
Inhibidores de CDK4/6; Cáncer de mama con receptor hormonal positivo; Cáncer de mama metastásico
dc.description.abstract
CDK4/6 inhibitors; Hormone receptor-positive breast cancer; Metastatic breast cancer
dc.description.abstract
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors’ addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level.
dc.description.abstract
This research received no external funding.
dc.format
application/pdf
dc.relation
Cancers;12(9)
dc.relation
https://www.mdpi.com/2072-6694/12/9/2480
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
